Deficiencies or abnormalities in any one factor can slow the overall process, increasing the risk of hemorrhage. The coagulation factors are numbered in the order of their discovery. There are 13 numerals but only 12 factors. Factor VI was subsequently found to be part of another factor. Extraction and downstream processing of plant-derived recombinant proteins. In-depth comparison of N -glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
Generation of biologically active multi-sialylated recombinant human EPOFc in plants. PLoS One 8 : e Glyco-engineering in plants to produce human-like N-glycan structures.
In planta protein sialylation through overexpression of the respective mammalian pathway. Economic costs of hemophilia and the impact of prophylactic treatment on patient management.
Care 22 S—S Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Heal. Molecular cloning of the gene for human anti-haemophilic factor IX.
Nature — Recombinant human thrombin: in surgical hemostasis. BioDrugs 23 — Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds. Transgenic Res.
Engineering of N. BMC Biotechnol. Glyco-engineering for biopharmaceutical production in moss bioreactors. Glycoprotein production in moss bioreactors. Plant Cell Rep. Expression of factor VIII by murine liver sinusoidal endothelial cells. The relationship of N -linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. Cell Biol. The levels of endoplasmic reticulum proteins and ATP affect folding and secretion of selective proteins.
Biologicals 22 — Gene therapy for hemophilia: what does the future hold? Antibodies from plants for bionanomaterials. Wiley Interdiscip. Reconstitution of human factor VIII from isolated subunits. Factor VIII structure and function.
Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 93 — Expression of functional human coagulation factor XIII A-domain in plant cell suspensions and whole plants. Protein Exp. Protein Sci. Characterization of the human factor VIII gene. Plant-specific glycosylation patterns in the context of therapeutic protein production.
Hemotherapy 45 86— Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins. Blood 85 — Transgenic plant-derived human blood coagulation factors. PCT Int. Patent number : CAA1. Vitamin K-dependent carboxylation.
Glyco-engineering of moss lacking plant-specific sugar residues. Plant Biol. Factor XIII deficiency. Regulation of factor VIII expression and activity by von willebrand factor. Post-translational modifications required for coagulation factor secretion and function.
Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
Haemophilia 11 84— Factor XIII: novel structural and functional aspects. Gorr G. Targeted knockout of Physcomitrella lacking plantspecific immunogenic N -glycans.
Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. Expression and assembly of largest foreign protein in chloroplasts: oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in hemophilia A mice. Blood 57— Gene Ther. Transcriptional regulation in plants.
Encyclopedia Life Sci. What is all that thrombin for? The hemophilias-from royal genes to gene therapy. Production of complex viral glycoproteins in plants as vaccine immunogens. Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science — Immunoglobulin binding protein BiP function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins.
Factor XIII and adipocyte biology. Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites. Hsu H. Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. Ludeman J. Cell Biol. Broze G. Regulation of blood coagulation by protease inhibitors. Glauser B. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
Rezaie A. Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition. Huang X. Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor ZPI as an inhibitor of membrane-associated factor Xa. Lee C. Rai R. Perspectives on factor Xa inhibition. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.
Wang S. The extended interactions and Gla domain of blood coagulation factor Xa. Becker R. Development of DXa, a novel direct factor Xa antagonist, in cardiovascular disease.
Lopopolo G. Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. Willardsen J. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. Hirayama F. Discovery of N -[2-hydroxy 4-methoxybenzamido phenyl] 4-methyl-1,4-diazepanyl benzamide Darexaban, YM as a potent and orally available factor Xa inhibitor.
Graff J. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. Pinto D. Discovery of 1- 4-methoxyphenyl oxo 4- 2-oxopiperidinyl phenyl -4,5,6,7-tetrahydro-1H-pyrazolo[3,4—c]pyridinecarboxamide Apixaban, BMS , a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Quan M. Murakami M. Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. Grundy J. Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa.
Talbot K. Enhanced fibrinolysis by proteolysed coagulation factor Xa. McMullen B. Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid.
Leytus S. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Padmanabhan K. Structure of human des factor Xa at 2. Kamata K. Structural basis for chemical inhibition of human blood coagulation factor Xa. Selander-Sunnerhagen M. How an epidermal growth factor EGF -like domain binds calcium. Sunnerhagen M. A combined NMR-small angle X-ray scattering study. Church W.
A simple purification of human factor X using a high affinity monoclonal antibody immunoadsorbant. Rudolph A. Expression, purification, and characterization of recombinant human factor X. Protein Expr. Brown M. Identification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for gamma-carboxyglutamyl Gla residues. Camire R. Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide.
Larson P. Kaufman R. Post-translational modifications required for coagulation factor secretion and function. Fernlund P. Beta-hydroxyaspartic acid in vitamin K-dependent proteins. Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase.
Prothrombin : is produced in the liver and is co - translationally modified in a vitamin K dependent reaction that converts ten glutamic acids on prothrombin to gamma carboxy glutamic acid. Where are albumin, fibrinogen and prothrombin made? Biology Molecular Biology Basics Proteins.
Linica Uday. Nov 17,
0コメント